Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

December 9, 2026

Study Completion Date

December 9, 2026

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

Ruxolitinib Cream

Ruxolitinib cream applied topically to the affected area as a thin film twice daily.

Trial Locations (20)

10019

NOT_YET_RECRUITING

Equity Medical, Llc, New York

19103

NOT_YET_RECRUITING

Paddington Testing Co Inc, Philadelphia

31904

NOT_YET_RECRUITING

Lane Dermatology and Dermatologic Surgery, Columbus

32771

RECRUITING

International Clinical Research Tennessee Llc, Sanford

33172

RECRUITING

Lenus Research Medical Group, Llc, Sweetwater

33609

RECRUITING

Trueblue Clinical Research, Tampa

42104

NOT_YET_RECRUITING

Equity Medical, Llc, Bowling Green

43213

NOT_YET_RECRUITING

Centricity Research Columbus Ohio Multispecialty Office, Columbus

48084

NOT_YET_RECRUITING

Revival Research Institute, Llc Troy, Troy

58103

RECRUITING

Red River Research Partners, Fargo

65613

NOT_YET_RECRUITING

Red River Research Partners, Bolivar

70809

RECRUITING

Delricht Research, Baton Rouge

73118

RECRUITING

Unity Clinical Research, Oklahoma City

78759

WITHDRAWN

Dermresearch, Inc., Austin

80109

NOT_YET_RECRUITING

Clarity Dermatology, Castle Rock

85008

NOT_YET_RECRUITING

Saguaro Dermatology, Phoenix

91320

NOT_YET_RECRUITING

Clinical Trials Research Institute, Thousand Oaks

91324

RECRUITING

Amicis Research Center Valencia, Northridge

92708

NOT_YET_RECRUITING

First Oc Dermatology, Fountain Valley

10012-1354

NOT_YET_RECRUITING

Dr Bobby Buka, Md Greenwich Village, New York

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Incyte Corporation

INDUSTRY